Efficacy and safety of cosibelimab, an anti���PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.

Citation

• Clingan, P. R., Brungs, D., Arnold, S., Coward, J., Fourie, S. J., Harris, D. L., . . . Desai, J. (2022). Efficacy and safety of cosibelimab, an anti���PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.. Journal of Clinical Oncology, 40(16_suppl), 9537. doi:10.1200/jco.2022.40.16_suppl.9537

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.9537

Web Of Science Accession Number

Start Page

• 9537

End Page

• 9537

Volume

• 40

Issue

• 16_suppl

Place Of Publication

Abstract

UOW Authors

•   Brungs, Daniel
•   Clingan, Phillip (external author)

Publication Date

• 2022

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Clingan, P. R., Brungs, D., Arnold, S., Coward, J., Fourie, S. J., Harris, D. L., . . . Desai, J. (2022). Efficacy and safety of cosibelimab, an anti���PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.. Journal of Clinical Oncology, 40(16_suppl), 9537. doi:10.1200/jco.2022.40.16_suppl.9537

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.9537

Web Of Science Accession Number

Start Page

• 9537

End Page

• 9537

Volume

• 40

Issue

• 16_suppl

Place Of Publication